Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation

The aim of this study was to assess the morphological characteristics and immunohistochemical profile of breast carcinomas with basal and myoepithelial phenotypes to obtain a better understanding of their biological behaviour and nature. One thousand nine hundred and forty‐four invasive breast carci...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pathology 2006-03, Vol.208 (4), p.495-506
Hauptverfasser: Rakha, EA, Putti, TC, Abd El-Rehim, DM, Paish, C, Green, AR, Powe, DG, Lee, AH, Robertson, JF, Ellis, IO
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 506
container_issue 4
container_start_page 495
container_title The Journal of pathology
container_volume 208
creator Rakha, EA
Putti, TC
Abd El-Rehim, DM
Paish, C
Green, AR
Powe, DG
Lee, AH
Robertson, JF
Ellis, IO
description The aim of this study was to assess the morphological characteristics and immunohistochemical profile of breast carcinomas with basal and myoepithelial phenotypes to obtain a better understanding of their biological behaviour and nature. One thousand nine hundred and forty‐four invasive breast carcinomas were examined, using tissue microarray (TMA) technology and immunohistochemistry, to identify those tumours that showed basal and myoepithelial phenotypes, and their immunophenotype profile was characterized using a variety of markers. In addition, haematoxylin and eosin‐stained sections of these tumours were studied for several morphological parameters. The findings were correlated with patient and tumour characteristics and outcome data. Tumours were classified into two groups: (1) tumours with basal phenotype [expressing one or both basal markers (CK5/6 and/or CK14)] and (2) tumours with myoepithelial phenotype (expressing SMA and/or p63). Group 1 was further subdivided into two subgroups: (A) dominant basal pattern (more than 50% of cells positive) and (B) basal characteristics (10–50% of cells positive). Group 1 tumours constituted 18.6% (8.6% and 10% for groups 1A and 1B, respectively) and group 2 constituted 13.7% of the cases. In both groups, the most common histological types were ductal/no specific type, tubular mixed and medullary‐like carcinomas; the majority of these tumours were grade 3. There were positive associations with adenoid cystic growth pattern, loss of tubule formation, marked cellular pleomorphism, poorer Nottingham prognostic index, and development of distant metastasis. In addition, associations were found with loss of expression of steroid hormone receptors and FHIT proteins and positive expression of p53 and EGFR. The most common characteristics in group 1 were larger size, high‐grade comedo‐type necrosis, development of tumour recurrence, and absence of lymph node disease. Group 2 tumours were more common in younger patients and were associated with central acellular zones, basaloid change, and positive E‐cadherin protein expression. Group 1 characteristics were associated with both reduced overall survival (OS) [log rank (LR) = 22.5, p < 0.001] and reduced disease‐free interval (DFI) (LR = 30.1, p < 0.001), while group 2 characteristics showed an association with OS (LR = 5, p = 0.02) but not with DFI. Multivariate analysis showed that basal, but not myoepithelial, phenotype has an independent value in predicting outcome. Br
doi_str_mv 10.1002/path.1916
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67660979</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67660979</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3916-2704a5c60088a9b02dacabd6dacbd519d4e289c72721abb0dad1aa1c18c1da313</originalsourceid><addsrcrecordid>eNp1kEtP5DAQhC0EglngwB9AuYC0h4Cdhx0f0QgGpPA48JC4WB3bYQxJHOyM2Pz79WgiOHFqqfqrblUhdETwGcE4Oe9hWJ4RTugWmhHMacwLTrfRLOySOM0I20N_vH_HGHOe57toj9As4SnPZqi9ta5f2sa-GQlNBJ2KTNuuOtsvdWeHsTcyiNCM3vjI1lHlNPghkuCk6WwLPvoywzKqwE_udrS6D5JuTFCUqWvtdDcYGIztDtBODY3Xh9PcR09Xl4_z67i8X9zML8pYpiFFnDCcQS4pxkUBvMKJAgmVomFUKidcZTopuGQJSwhUFVagCACRpJBEQUrSfXS6uds7-7nSfhCt8VI3DXTarrygjFLMGQ_g3w0onfXe6Vr0zrTgRkGwWHcr1t2KdbeBPZ6OrqpWqx9yKjMAJxMAPpRZO-ik8T8cyzjndM2db7gv0-jx94_i4eLxenodbxzGD_rftwPcR4iSsly83C1E-bBYvJbPpWDpf2QMo78</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67660979</pqid></control><display><type>article</type><title>Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation</title><source>Access via Wiley Online Library</source><source>MEDLINE</source><creator>Rakha, EA ; Putti, TC ; Abd El-Rehim, DM ; Paish, C ; Green, AR ; Powe, DG ; Lee, AH ; Robertson, JF ; Ellis, IO</creator><creatorcontrib>Rakha, EA ; Putti, TC ; Abd El-Rehim, DM ; Paish, C ; Green, AR ; Powe, DG ; Lee, AH ; Robertson, JF ; Ellis, IO</creatorcontrib><description>The aim of this study was to assess the morphological characteristics and immunohistochemical profile of breast carcinomas with basal and myoepithelial phenotypes to obtain a better understanding of their biological behaviour and nature. One thousand nine hundred and forty‐four invasive breast carcinomas were examined, using tissue microarray (TMA) technology and immunohistochemistry, to identify those tumours that showed basal and myoepithelial phenotypes, and their immunophenotype profile was characterized using a variety of markers. In addition, haematoxylin and eosin‐stained sections of these tumours were studied for several morphological parameters. The findings were correlated with patient and tumour characteristics and outcome data. Tumours were classified into two groups: (1) tumours with basal phenotype [expressing one or both basal markers (CK5/6 and/or CK14)] and (2) tumours with myoepithelial phenotype (expressing SMA and/or p63). Group 1 was further subdivided into two subgroups: (A) dominant basal pattern (more than 50% of cells positive) and (B) basal characteristics (10–50% of cells positive). Group 1 tumours constituted 18.6% (8.6% and 10% for groups 1A and 1B, respectively) and group 2 constituted 13.7% of the cases. In both groups, the most common histological types were ductal/no specific type, tubular mixed and medullary‐like carcinomas; the majority of these tumours were grade 3. There were positive associations with adenoid cystic growth pattern, loss of tubule formation, marked cellular pleomorphism, poorer Nottingham prognostic index, and development of distant metastasis. In addition, associations were found with loss of expression of steroid hormone receptors and FHIT proteins and positive expression of p53 and EGFR. The most common characteristics in group 1 were larger size, high‐grade comedo‐type necrosis, development of tumour recurrence, and absence of lymph node disease. Group 2 tumours were more common in younger patients and were associated with central acellular zones, basaloid change, and positive E‐cadherin protein expression. Group 1 characteristics were associated with both reduced overall survival (OS) [log rank (LR) = 22.5, p &lt; 0.001] and reduced disease‐free interval (DFI) (LR = 30.1, p &lt; 0.001), while group 2 characteristics showed an association with OS (LR = 5, p = 0.02) but not with DFI. Multivariate analysis showed that basal, but not myoepithelial, phenotype has an independent value in predicting outcome. Breast cancers with basal and myoepithelial phenotypes are distinct groups of tumours that share some common morphological features and an association with poor prognosis. The basal rather than the myoepithelial phenotype has the strongest relationship with patient outcome. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.1916</identifier><identifier>PMID: 16429394</identifier><identifier>CODEN: JPTLAS</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Actins - genetics ; Adult ; Age Factors ; Aged ; basal ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; breast carcinoma ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cadherins - analysis ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - mortality ; Carcinoma, Ductal, Breast - pathology ; Cell Differentiation ; Disease-Free Survival ; Female ; Genes, p53 ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; immunoprofile ; Investigative techniques, diagnostic techniques (general aspects) ; Keratins - genetics ; Mammary gland diseases ; Medical sciences ; Middle Aged ; morphology ; Multivariate Analysis ; myoepithelial ; Myoepithelioma - metabolism ; Myoepithelioma - mortality ; Myoepithelioma - pathology ; Necrosis ; Neoplasms, Basal Cell - immunology ; Neoplasms, Basal Cell - mortality ; Neoplasms, Basal Cell - pathology ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Receptor, Epidermal Growth Factor - analysis ; Receptors, Androgen - analysis ; Staining and Labeling ; Survival Rate ; Tumors</subject><ispartof>The Journal of pathology, 2006-03, Vol.208 (4), p.495-506</ispartof><rights>Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3916-2704a5c60088a9b02dacabd6dacbd519d4e289c72721abb0dad1aa1c18c1da313</citedby><cites>FETCH-LOGICAL-c3916-2704a5c60088a9b02dacabd6dacbd519d4e289c72721abb0dad1aa1c18c1da313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpath.1916$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpath.1916$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17499964$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16429394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rakha, EA</creatorcontrib><creatorcontrib>Putti, TC</creatorcontrib><creatorcontrib>Abd El-Rehim, DM</creatorcontrib><creatorcontrib>Paish, C</creatorcontrib><creatorcontrib>Green, AR</creatorcontrib><creatorcontrib>Powe, DG</creatorcontrib><creatorcontrib>Lee, AH</creatorcontrib><creatorcontrib>Robertson, JF</creatorcontrib><creatorcontrib>Ellis, IO</creatorcontrib><title>Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation</title><title>The Journal of pathology</title><addtitle>J. Pathol</addtitle><description>The aim of this study was to assess the morphological characteristics and immunohistochemical profile of breast carcinomas with basal and myoepithelial phenotypes to obtain a better understanding of their biological behaviour and nature. One thousand nine hundred and forty‐four invasive breast carcinomas were examined, using tissue microarray (TMA) technology and immunohistochemistry, to identify those tumours that showed basal and myoepithelial phenotypes, and their immunophenotype profile was characterized using a variety of markers. In addition, haematoxylin and eosin‐stained sections of these tumours were studied for several morphological parameters. The findings were correlated with patient and tumour characteristics and outcome data. Tumours were classified into two groups: (1) tumours with basal phenotype [expressing one or both basal markers (CK5/6 and/or CK14)] and (2) tumours with myoepithelial phenotype (expressing SMA and/or p63). Group 1 was further subdivided into two subgroups: (A) dominant basal pattern (more than 50% of cells positive) and (B) basal characteristics (10–50% of cells positive). Group 1 tumours constituted 18.6% (8.6% and 10% for groups 1A and 1B, respectively) and group 2 constituted 13.7% of the cases. In both groups, the most common histological types were ductal/no specific type, tubular mixed and medullary‐like carcinomas; the majority of these tumours were grade 3. There were positive associations with adenoid cystic growth pattern, loss of tubule formation, marked cellular pleomorphism, poorer Nottingham prognostic index, and development of distant metastasis. In addition, associations were found with loss of expression of steroid hormone receptors and FHIT proteins and positive expression of p53 and EGFR. The most common characteristics in group 1 were larger size, high‐grade comedo‐type necrosis, development of tumour recurrence, and absence of lymph node disease. Group 2 tumours were more common in younger patients and were associated with central acellular zones, basaloid change, and positive E‐cadherin protein expression. Group 1 characteristics were associated with both reduced overall survival (OS) [log rank (LR) = 22.5, p &lt; 0.001] and reduced disease‐free interval (DFI) (LR = 30.1, p &lt; 0.001), while group 2 characteristics showed an association with OS (LR = 5, p = 0.02) but not with DFI. Multivariate analysis showed that basal, but not myoepithelial, phenotype has an independent value in predicting outcome. Breast cancers with basal and myoepithelial phenotypes are distinct groups of tumours that share some common morphological features and an association with poor prognosis. The basal rather than the myoepithelial phenotype has the strongest relationship with patient outcome. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</description><subject>Actins - genetics</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>basal</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>breast carcinoma</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cadherins - analysis</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - mortality</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Cell Differentiation</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Genes, p53</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>immunoprofile</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Keratins - genetics</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>morphology</subject><subject>Multivariate Analysis</subject><subject>myoepithelial</subject><subject>Myoepithelioma - metabolism</subject><subject>Myoepithelioma - mortality</subject><subject>Myoepithelioma - pathology</subject><subject>Necrosis</subject><subject>Neoplasms, Basal Cell - immunology</subject><subject>Neoplasms, Basal Cell - mortality</subject><subject>Neoplasms, Basal Cell - pathology</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Receptor, Epidermal Growth Factor - analysis</subject><subject>Receptors, Androgen - analysis</subject><subject>Staining and Labeling</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtP5DAQhC0EglngwB9AuYC0h4Cdhx0f0QgGpPA48JC4WB3bYQxJHOyM2Pz79WgiOHFqqfqrblUhdETwGcE4Oe9hWJ4RTugWmhHMacwLTrfRLOySOM0I20N_vH_HGHOe57toj9As4SnPZqi9ta5f2sa-GQlNBJ2KTNuuOtsvdWeHsTcyiNCM3vjI1lHlNPghkuCk6WwLPvoywzKqwE_udrS6D5JuTFCUqWvtdDcYGIztDtBODY3Xh9PcR09Xl4_z67i8X9zML8pYpiFFnDCcQS4pxkUBvMKJAgmVomFUKidcZTopuGQJSwhUFVagCACRpJBEQUrSfXS6uds7-7nSfhCt8VI3DXTarrygjFLMGQ_g3w0onfXe6Vr0zrTgRkGwWHcr1t2KdbeBPZ6OrqpWqx9yKjMAJxMAPpRZO-ik8T8cyzjndM2db7gv0-jx94_i4eLxenodbxzGD_rftwPcR4iSsly83C1E-bBYvJbPpWDpf2QMo78</recordid><startdate>200603</startdate><enddate>200603</enddate><creator>Rakha, EA</creator><creator>Putti, TC</creator><creator>Abd El-Rehim, DM</creator><creator>Paish, C</creator><creator>Green, AR</creator><creator>Powe, DG</creator><creator>Lee, AH</creator><creator>Robertson, JF</creator><creator>Ellis, IO</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200603</creationdate><title>Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation</title><author>Rakha, EA ; Putti, TC ; Abd El-Rehim, DM ; Paish, C ; Green, AR ; Powe, DG ; Lee, AH ; Robertson, JF ; Ellis, IO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3916-2704a5c60088a9b02dacabd6dacbd519d4e289c72721abb0dad1aa1c18c1da313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Actins - genetics</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>basal</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>breast carcinoma</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cadherins - analysis</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - mortality</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Cell Differentiation</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Genes, p53</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>immunoprofile</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Keratins - genetics</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>morphology</topic><topic>Multivariate Analysis</topic><topic>myoepithelial</topic><topic>Myoepithelioma - metabolism</topic><topic>Myoepithelioma - mortality</topic><topic>Myoepithelioma - pathology</topic><topic>Necrosis</topic><topic>Neoplasms, Basal Cell - immunology</topic><topic>Neoplasms, Basal Cell - mortality</topic><topic>Neoplasms, Basal Cell - pathology</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Receptor, Epidermal Growth Factor - analysis</topic><topic>Receptors, Androgen - analysis</topic><topic>Staining and Labeling</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rakha, EA</creatorcontrib><creatorcontrib>Putti, TC</creatorcontrib><creatorcontrib>Abd El-Rehim, DM</creatorcontrib><creatorcontrib>Paish, C</creatorcontrib><creatorcontrib>Green, AR</creatorcontrib><creatorcontrib>Powe, DG</creatorcontrib><creatorcontrib>Lee, AH</creatorcontrib><creatorcontrib>Robertson, JF</creatorcontrib><creatorcontrib>Ellis, IO</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rakha, EA</au><au>Putti, TC</au><au>Abd El-Rehim, DM</au><au>Paish, C</au><au>Green, AR</au><au>Powe, DG</au><au>Lee, AH</au><au>Robertson, JF</au><au>Ellis, IO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J. Pathol</addtitle><date>2006-03</date><risdate>2006</risdate><volume>208</volume><issue>4</issue><spage>495</spage><epage>506</epage><pages>495-506</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><coden>JPTLAS</coden><abstract>The aim of this study was to assess the morphological characteristics and immunohistochemical profile of breast carcinomas with basal and myoepithelial phenotypes to obtain a better understanding of their biological behaviour and nature. One thousand nine hundred and forty‐four invasive breast carcinomas were examined, using tissue microarray (TMA) technology and immunohistochemistry, to identify those tumours that showed basal and myoepithelial phenotypes, and their immunophenotype profile was characterized using a variety of markers. In addition, haematoxylin and eosin‐stained sections of these tumours were studied for several morphological parameters. The findings were correlated with patient and tumour characteristics and outcome data. Tumours were classified into two groups: (1) tumours with basal phenotype [expressing one or both basal markers (CK5/6 and/or CK14)] and (2) tumours with myoepithelial phenotype (expressing SMA and/or p63). Group 1 was further subdivided into two subgroups: (A) dominant basal pattern (more than 50% of cells positive) and (B) basal characteristics (10–50% of cells positive). Group 1 tumours constituted 18.6% (8.6% and 10% for groups 1A and 1B, respectively) and group 2 constituted 13.7% of the cases. In both groups, the most common histological types were ductal/no specific type, tubular mixed and medullary‐like carcinomas; the majority of these tumours were grade 3. There were positive associations with adenoid cystic growth pattern, loss of tubule formation, marked cellular pleomorphism, poorer Nottingham prognostic index, and development of distant metastasis. In addition, associations were found with loss of expression of steroid hormone receptors and FHIT proteins and positive expression of p53 and EGFR. The most common characteristics in group 1 were larger size, high‐grade comedo‐type necrosis, development of tumour recurrence, and absence of lymph node disease. Group 2 tumours were more common in younger patients and were associated with central acellular zones, basaloid change, and positive E‐cadherin protein expression. Group 1 characteristics were associated with both reduced overall survival (OS) [log rank (LR) = 22.5, p &lt; 0.001] and reduced disease‐free interval (DFI) (LR = 30.1, p &lt; 0.001), while group 2 characteristics showed an association with OS (LR = 5, p = 0.02) but not with DFI. Multivariate analysis showed that basal, but not myoepithelial, phenotype has an independent value in predicting outcome. Breast cancers with basal and myoepithelial phenotypes are distinct groups of tumours that share some common morphological features and an association with poor prognosis. The basal rather than the myoepithelial phenotype has the strongest relationship with patient outcome. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>16429394</pmid><doi>10.1002/path.1916</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3417
ispartof The Journal of pathology, 2006-03, Vol.208 (4), p.495-506
issn 0022-3417
1096-9896
language eng
recordid cdi_proquest_miscellaneous_67660979
source Access via Wiley Online Library; MEDLINE
subjects Actins - genetics
Adult
Age Factors
Aged
basal
Biological and medical sciences
Biomarkers, Tumor - analysis
breast carcinoma
Breast Neoplasms - metabolism
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Cadherins - analysis
Carcinoma, Ductal, Breast - metabolism
Carcinoma, Ductal, Breast - mortality
Carcinoma, Ductal, Breast - pathology
Cell Differentiation
Disease-Free Survival
Female
Genes, p53
Gynecology. Andrology. Obstetrics
Humans
Immunohistochemistry
immunoprofile
Investigative techniques, diagnostic techniques (general aspects)
Keratins - genetics
Mammary gland diseases
Medical sciences
Middle Aged
morphology
Multivariate Analysis
myoepithelial
Myoepithelioma - metabolism
Myoepithelioma - mortality
Myoepithelioma - pathology
Necrosis
Neoplasms, Basal Cell - immunology
Neoplasms, Basal Cell - mortality
Neoplasms, Basal Cell - pathology
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Receptor, Epidermal Growth Factor - analysis
Receptors, Androgen - analysis
Staining and Labeling
Survival Rate
Tumors
title Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T13%3A43%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Morphological%20and%20immunophenotypic%20analysis%20of%20breast%20carcinomas%20with%20basal%20and%20myoepithelial%20differentiation&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Rakha,%20EA&rft.date=2006-03&rft.volume=208&rft.issue=4&rft.spage=495&rft.epage=506&rft.pages=495-506&rft.issn=0022-3417&rft.eissn=1096-9896&rft.coden=JPTLAS&rft_id=info:doi/10.1002/path.1916&rft_dat=%3Cproquest_cross%3E67660979%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67660979&rft_id=info:pmid/16429394&rfr_iscdi=true